These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 24302556)
1. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Malchers F; Dietlein F; Schöttle J; Lu X; Nogova L; Albus K; Fernandez-Cuesta L; Heuckmann JM; Gautschi O; Diebold J; Plenker D; Gardizi M; Scheffler M; Bos M; Seidel D; Leenders F; Richters A; Peifer M; Florin A; Mainkar PS; Karre N; Chandrasekhar S; George J; Silling S; Rauh D; Zander T; Ullrich RT; Reinhardt HC; Ringeisen F; Büttner R; Heukamp LC; Wolf J; Thomas RK Cancer Discov; 2014 Feb; 4(2):246-57. PubMed ID: 24302556 [TBL] [Abstract][Full Text] [Related]
2. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034 [TBL] [Abstract][Full Text] [Related]
3. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Primary Drug Resistance in Malchers F; Ercanoglu M; Schütte D; Castiglione R; Tischler V; Michels S; Dahmen I; Brägelmann J; Menon R; Heuckmann JM; George J; Ansén S; Sos ML; Soltermann A; Peifer M; Wolf J; Büttner R; Thomas RK Clin Cancer Res; 2017 Sep; 23(18):5527-5536. PubMed ID: 28630215 [No Abstract] [Full Text] [Related]
5. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer. Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756 [TBL] [Abstract][Full Text] [Related]
6. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459 [TBL] [Abstract][Full Text] [Related]
7. Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon. Rooney C; Geh C; Williams V; Heuckmann JM; Menon R; Schneider P; Al-Kadhimi K; Dymond M; Smith NR; Baker D; French T; Smith PD; Harrington EA; Barrett JC; Kilgour E PLoS One; 2016; 11(2):e0149628. PubMed ID: 26905262 [TBL] [Abstract][Full Text] [Related]
8. MYCxing it up with FGFR1 in squamous cell lung cancer. Lockwood W; Politi K Cancer Discov; 2014 Feb; 4(2):152-4. PubMed ID: 24501305 [TBL] [Abstract][Full Text] [Related]
9. A large-scale RNAi-based mouse tumorigenesis screen identifies new lung cancer tumor suppressors that repress FGFR signaling. Lin L; Chamberlain L; Pak ML; Nagarajan A; Gupta R; Zhu LJ; Wright CM; Fong KM; Wajapeyee N; Green MR Cancer Discov; 2014 Oct; 4(10):1168-81. PubMed ID: 25015643 [TBL] [Abstract][Full Text] [Related]
10. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Ren M; Hong M; Liu G; Wang H; Patel V; Biddinger P; Silva J; Cowell J; Hao Z Oncol Rep; 2013 Jun; 29(6):2181-90. PubMed ID: 23563700 [TBL] [Abstract][Full Text] [Related]
11. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Preusser M; Berghoff AS; Berger W; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckmann K; Wöhrer A; Hackl M; von Deimling A; Streubel B; Birner P Lung Cancer; 2014 Jan; 83(1):83-9. PubMed ID: 24183471 [TBL] [Abstract][Full Text] [Related]
12. A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Paik PK; Shen R; Berger MF; Ferry D; Soria JC; Mathewson A; Rooney C; Smith NR; Cullberg M; Kilgour E; Landers D; Frewer P; Brooks N; André F Clin Cancer Res; 2017 Sep; 23(18):5366-5373. PubMed ID: 28615371 [No Abstract] [Full Text] [Related]
13. FGFR1 Amplification in Squamous Cell Carcinoma of the Lung with Correlation of Primary and Metastatic Tumor Status. Monaco SE; Rodriguez EF; Mahaffey AL; Dacic S Am J Clin Pathol; 2016 Jan; 145(1):55-61. PubMed ID: 26712871 [TBL] [Abstract][Full Text] [Related]
14. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Wynes MW; Hinz TK; Gao D; Martini M; Marek LA; Ware KE; Edwards MG; Böhm D; Perner S; Helfrich BA; Dziadziuszko R; Jassem J; Wojtylak S; Sejda A; Gozgit JM; Bunn PA; Camidge DR; Tan AC; Hirsch FR; Heasley LE Clin Cancer Res; 2014 Jun; 20(12):3299-309. PubMed ID: 24771645 [TBL] [Abstract][Full Text] [Related]
16. Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. Weeden CE; Holik AZ; Young RJ; Ma SB; Garnier JM; Fox SB; Antippa P; Irving LB; Steinfort DP; Wright GM; Russell PA; Ritchie ME; Burns CJ; Solomon B; Asselin-Labat ML Mol Cancer Ther; 2017 Aug; 16(8):1610-1622. PubMed ID: 28611104 [TBL] [Abstract][Full Text] [Related]
17. FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway. Ji W; Yu Y; Li Z; Wang G; Li F; Xia W; Lu S Oncotarget; 2016 Mar; 7(12):15118-34. PubMed ID: 26936993 [TBL] [Abstract][Full Text] [Related]
18. CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for Yang Z; Liang SQ; Yang H; Xu D; Bruggmann R; Gao Y; Deng H; Berezowska S; Hall SRR; Marti TM; Kocher GJ; Zhou Q; Schmid RA; Peng RW Cancer Res; 2021 Jun; 81(11):3121-3133. PubMed ID: 33685992 [TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. Kim HR; Kim DJ; Kang DR; Lee JG; Lim SM; Lee CY; Rha SY; Bae MK; Lee YJ; Kim SH; Ha SJ; Soo RA; Chung KY; Kim JH; Lee JH; Shim HS; Cho BC J Clin Oncol; 2013 Feb; 31(6):731-7. PubMed ID: 23182986 [TBL] [Abstract][Full Text] [Related]
20. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Shiang CY; Qi Y; Wang B; Lazar V; Wang J; Fraser Symmans W; Hortobagyi GN; Andre F; Pusztai L Breast Cancer Res Treat; 2010 Oct; 123(3):747-55. PubMed ID: 20024612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]